Loading
A phase 3 trial of Cadonilimab, CAPOX, Capecitabine in colorectal cancer, run by Akeso, now recruiting.
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer is a phase 3 interventional study registered as NCT07412613 by Akeso, with 386 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-06-15. Interventions recorded: Cadonilimab (AK104), Oxaliplatin, Capecitabine, 5- Fluorouracil, Calcium Folinate. Conditions listed: Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Leucovorin (folinic acid), Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Leucovorin (folinic acid), CAPOX (capecitabine, oxaliplatin), Capecitabine, Colorectal cancer.
Shares Cadonilimab, CAPOX (capecitabine, oxaliplatin), Capecitabine, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/